Veracyte SVP Sells Over $236K in Stock

Insider selling activity reported for the genomic diagnostics company.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Veracyte, Inc. (NASDAQ:VCYT) SVP Annie Mcguire sold 6,658 shares of the company's stock on March 4th for a total value of $236,691.90. Following the transaction, Mcguire now owns 94,706 shares of the company, valued at approximately $3,366,798.30. This represents a 6.57% decrease in her ownership stake.

Why it matters

Insider selling activity can provide insights into management's views on a company's prospects and valuation. While not definitive, significant insider sales may signal that executives believe the stock is overvalued or that they want to diversify their personal holdings.

The details

The stock sale was disclosed in a filing with the Securities & Exchange Commission. Mcguire sold the shares at an average price of $35.55. Veracyte is a genomic diagnostics company focused on improving diagnostic accuracy through advanced molecular testing, particularly in areas like thyroid, lung, and other diseases.

  • The stock sale occurred on March 4, 2026.

The players

Annie Mcguire

SVP at Veracyte, Inc.

Veracyte, Inc.

A genomic diagnostics company focused on improving diagnostic accuracy through advanced molecular testing.

Got photos? Submit your photos here. ›

The takeaway

This insider selling activity suggests that Veracyte's SVP may believe the company's stock is currently overvalued, though it's difficult to draw definitive conclusions from a single transaction. Investors should continue to monitor Veracyte's financial performance and any further insider trading disclosures.